Welcome back, everyone. We have an update from MetaVia Inc. Trades on the NASDAQ under the symbol MTVA. It's a clinical stage biotech company focused on transforming cardiometabolic diseases. Happy to welcome President CEO, H.H. Kim, and the CFO, Marshall Woodworth. Welcome, gentlemen. We're looking forward to hearing your update today. Thank you, Anna. Thanks everyone for joining. We have 10 minutes to give you a brief update on what we have been doing. We have been attending two major medical conferences recently. One being EASL, the European Liver Meeting, and in that conference, we did one poster presentation on our DA-1726. It's the GLP-1 glucagon dual agonist with the unique balance of 3: 1, and the new data release on that poster was on the QTcF, the heart rate. In the past, there are data showing that glucagon may increase heart rates, and it was a pretty important safety data that we collected during our phase I, and we have not seen any abnormalities in the heart rates, which is a very good sign. After that, we attended the ADA, American Diabetes Association conference over in New Orleans, and we had three posters there. On DA-1726, the obesity drug, the new data on the poster was on the PK. It's a textbook-like PK profile, very dose-dependent. That was great. Just on 1726, we are currently running a phase I, part three, which focuses on titration and plus a higher dose level of 64 mg. We had the first patient in in April, and we are very smoothly going through the titration and hopefully we will be able to have the data of the 16-week study out before end of this year. I would like to take a little more time on the ADA posters on our oral asset, which is vanoglipol, the GPR119 small molecule oral drug that we finished a phase IIa in MASH patients. We met the primary endpoints, but we did have two posters on vanoglipol. All of them are non-clinical. It was on the combination potential of this drug. The MASH indication itself with amazing job by Madrigal. The resmetirom drug is selling very well. It's really pioneering the MASH market. The competition is getting higher and higher. semaglutide, the GLP-1 from Novo Nordisk, got approval to be prescribed on MASH as well. There are multiple other injectables out there, such as GLP-1/GIP, GLP-1 glucagon, and FGF21s all going into the MASH field. It's getting highly competitive. That's the reason why we are still actively searching for a combination of this drug to move into the MASH indication and potentially other indications as well. You can find these posters on our website. It has a lot more detail than this. This is just a highlight for this 10-minute session. I'll start with the poster 3043LB. This is vanoglipol plus resmetirom, the conditionally approved drug in MASH. The highlight of this study on mice was that when you look at the middle part, it is the weight. Mono arm of vanoglipol, mono arm of resmetirom control, everything through time in the study gained weight. The combination lost weight. How much? By 23.6% compared to control. This, and resmetirom. This is very different than what we have seen in clinic. Vanoglipol did not have significant weight loss effect, and resmetirom did not have weight loss effect as well. In combination, we have seen something very different. When you look at the left-hand corner, fat mass, lean mass. Lean mass has not changed, but fat mass went down by -43.5%. More importantly is the right-hand corner. This is the food intake. As you know, the GLP-1s out there, all of them, the weight loss is coming from appetite control. Look at this. Food intake combination actually ate more food than the control or the vanoglipol arm, and still had significant weight loss. Why is this? We are thinking that resmetirom, the THR-β agonist, does show energy expenditure. We believe that vanoglipol enhances that feature of resmetirom, which results in a significant weight loss. Just to go a little bit more into the MASH results, you can clearly see that the NAS improvement in the combination is better. Plus, when you look at the mono arms, they even had no change groups. The combo did not even have that, which is quite amazing. The liver steatosis as well, the combination had a lot better results compared to the mono arms of vano and resmetirom. This is quite significant results coming out from a combination, we will be exploring a little more into this potential combo as we speak. Another poster was on 2856LB on a metformin combination, and you can see that the monotherapy did not lose weight while combination lost -16.3% of the weight, and the fat mass reduction is quite significant. We believe this is due to increase in GLP-1 production and the Peptide YY. Peptide YY is known to have an effect on appetite control, and of course, as we know, GLP-1 has that as well. This combo is a little different than resmetirom combo because resmetirom combo, the appetite control was non-existent while losing weight, while this metformin combination actually had lowered food intake, which resulted in weight loss. Fasting glucose, of course, metformin, as you know, is a Type 2 diabetes agent, in combination with vanoglipol, the fasting glucose levels were all better than the mono arms. With these posters, we believe we have shown something for vanoglipol to move forward as a combination potential, we are looking into different angles, different agents out there to see how vanoglipol works with other Type 2 diabetes-approved drugs or even in MASH. Once we have that concluded and we have a path forward, we will meet with the FDA and push vanoglipol into another phase II in combination therapy. Marshall, could you give a brief update on our finances? Sure. Thanks, H.H. We have guided that we have cash into Q4 of this year. That guidance has not changed, but I think the more compelling way to think about how much cash we have is we have cash on hand to get us through the ongoing phase I, part three clinical trials for DA-1726, which is our obesity drug. H.H.? Thank you, Marshall. We are cruising through smoothly with the titrations that's in our part three for the obesity drug, DA-1726. We are looking for new strategies for vanoglipol. Please look at the posters on our website. It is very different than what we have seen in other combination with resmetirom and metformin. Thank you for your time. All right. Thank you, gentlemen. We appreciate your time and presentation on this matter. Great to learn more about MetaVia. Thank you for the update. We have lots of questions for you, but we'll send them to you so you can answer on your own. We certainly hope that you'll come back again real soon. Very good. Thank you. Thank you. All right. Everyone, stay with us. We'll be right back.